VBIV - מכפיל P/S עתידי VBI Vaccines Inc.

סמל תאגידי ולוגו של vbivaccines.com (VBIV)

The collapse of the partner network and subsequent bankruptcy led to a sell-off of VBI Vaccines Inc. (VBIV) assets, triggering a sharp spike in the business's forward P/S ratio. Despite its authority in developing brain cancer vaccines and its pricing power derived from the efficacy of its hepatitis B drug, the metric reached 0.20, confirming the company's systemic degradation.

VBI Vaccines Inc - יחס שווי שוק למכירות צפויות VBIV (תקופה 04.07.2022 - 17.08.2024)

VBI Vaccines (VBIV) - פילוחי מדדים ודוחות פיננסיים

- מחיר מניה ומחיר יעד קונצנזוס:
ניתוח פונדמנטלי של החברה:VBI Vaccines VBIV
מוצרים מיוצרים של vbivaccines.com

Patent protection for the VLP platform developed by VBI Vaccines Inc. (VBIV) to combat brain cancer and hepatitis B establishes a foundation of resilience reflected in the dynamics of the expected P/S ratio. This indicator benchmarks market capitalization against projected revenue, allowing investors to assess the market's confidence in future sales and determine the balance between speculative undervaluation and the risk of capital loss amid volatile forecasts.